Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Gains from Sales and Divestitures (2017 - 2022)

Usana Health Sciences (USNA) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $3000.0 as the latest value for Q1 2022.

  • On a quarterly basis, Gains from Sales and Divestitures rose 50.0% to $3000.0 in Q1 2022 year-over-year; TTM through Jan 2022 was $3000.0, a 50.0% increase, with the full-year FY2022 number at $3000.0, up 50.0% from a year prior.
  • Gains from Sales and Divestitures was $3000.0 for Q1 2022 at Usana Health Sciences, up from $2000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $59000.0 in Q4 2019 to a low of $2000.0 in Q1 2021.
  • A 4-year average of $22250.0 and a median of $14000.0 in 2018 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 150.0% in 2018, then plummeted 96.61% in 2021.
  • Usana Health Sciences' Gains from Sales and Divestitures stood at $25000.0 in 2018, then soared by 136.0% to $59000.0 in 2019, then tumbled by 96.61% to $2000.0 in 2021, then skyrocketed by 50.0% to $3000.0 in 2022.
  • Per Business Quant, the three most recent readings for USNA's Gains from Sales and Divestitures are $3000.0 (Q1 2022), $2000.0 (Q1 2021), and $59000.0 (Q4 2019).